Clinical application of bladder hyperthermic intracavitary chemotherapy

Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022099

Enrollment

Unknown

Registered

2019-03-25

Start date

2006-12-01

Completion date

Unknown

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

1+2:HIVEC combind with TUR + HIVEC

Eligibility

Sex/Gender

All

Age

37 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1) aged =18 years; 2) diagnosis of bladder cancer by cystoscopic observation, CT, and/or MRI; 3) diagnosis confirmed by histopathological examination of a biopsy specimen; 4) no radiation therapy in the 4 weeks preceding enrollment; and 5) no chemotherapy in the 4 weeks preceding enrollment.

Exclusion criteria

Exclusion criteria: 1) known or possible bladder metastasis from other primary cancer; 2) known or possible bladder tumor expanding through the serosa, invading locally or metastasizing to other organs; 3) known or potential pregnancy; or 4) active inflammation or infection.

Design outcomes

Primary

Measure	Time frame
Tumor size;Disease Free Survial(DFS);cumulative incidence rate (CIR);	—

Countries

China

Contacts

Public ContactMingchen Ba

Cancer Center of Guangzhou Medical University

bamingchen@126.com+86 13825017156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026